Brand Name | Status | Last Update |
---|---|---|
discount drug mart eye drops advanced relief | OTC monograph final | 2023-03-20 |
equalactin laxative | C200263 | 2024-12-18 |
equaline | OTC monograph not final | 2019-02-15 |
equaline 12 hour decongestant | ANDA | 2023-08-03 |
equaline acetaminophen | C200263 | 2024-11-13 |
equaline adult tussin | C200263 | 2024-11-10 |
equaline advanced relief eye drops | C200263 | 2023-12-20 |
equaline all day allergy | ANDA | 2023-08-02 |
equaline allergy | C200263 | 2024-09-29 |
equaline allergy relief | ANDA | 2024-12-10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney transplantation | D016030 | — | — | — | — | 1 | 8 | — | 9 |
Asthma | D001249 | EFO_0000270 | J45 | — | 5 | 3 | 1 | — | 8 |
Hypercholesterolemia | D006937 | — | — | — | — | 5 | 1 | 1 | 7 |
Neoplasms | D009369 | — | C80 | 1 | 3 | — | 1 | — | 4 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | 1 | 1 | 4 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 2 | 1 | 1 | 4 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 3 | — | 3 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 2 | — | 3 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 1 | 1 | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Syndrome | D013577 | — | — | — | 1 | 4 | — | — | 5 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | — | 3 | — | 1 | 4 |
Organ transplantation | D016377 | — | — | — | — | 2 | — | — | 2 |
Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 2 | — | — | 2 |
Cryopyrin-associated periodic syndromes | D056587 | — | M04.2 | — | — | 2 | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | — | — | 1 | — | — | 1 |
Preleukemia | D011289 | — | — | — | — | 1 | — | — | 1 |
Liver transplantation | D016031 | EFO_0010682 | — | — | — | 1 | — | — | 1 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | 1 | — | — | 1 |
Thrombocytopenic purpura | D011696 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 3 | 2 | — | — | — | 3 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | 2 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | 2 | 1 | — | — | — | 2 |
Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | — | — | — | 1 |
Diarrhea | D003967 | — | R19.7 | — | 1 | — | — | — | 1 |
Plexiform neurofibroma | D018318 | EFO_0000658 | — | 1 | 1 | — | — | — | 1 |
Neurofibromatoses | D017253 | — | Q85.00 | 1 | 1 | — | — | — | 1 |
Neurofibroma | D009455 | EFO_0000622 | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 1 | — | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
Iron-deficiency anemia | D018798 | — | D50 | 1 | — | — | — | — | 1 |
Iron deficiencies | D000090463 | — | E61.1 | 1 | — | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | — | — | — | — | 1 | 1 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
Drug common name | Aspartame |
INN | aspartame |
Description | Aspartame is a dipeptide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of methyl L-phenylalaninate. Commonly used as an artificial sweetener. It has a role as a sweetening agent, a nutraceutical, a micronutrient, a xenobiotic, an environmental contaminant, an apoptosis inhibitor and an EC 3.1.3.1 (alkaline phosphatase) inhibitor. It is a dipeptide, a carboxylic acid and a methyl ester. It is functionally related to a L-aspartic acid and a methyl L-phenylalaninate. It is a tautomer of an aspartame zwitterion. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(=O)O |
PDB | — |
CAS-ID | 22839-47-0 |
RxCUI | — |
ChEMBL ID | CHEMBL171679 |
ChEBI ID | 2877 |
PubChem CID | 134601 |
DrugBank | DB00168 |
UNII ID | Z0H242BBR1 (ChemIDplus, GSRS) |